

Scientific Program

DAY 1 : Thursday, 25 September, 2025

[Venue 1 - OHGI]

Opening Remarks		7:45-8:00
Kagawa Tatehiro		
Symposium 1 : Bile acid in health and disease		8:00-11:00
Chair	Tazuma Susumu (JR Hiroshima Hospital / Futabanosato Prefectural Hospital / Hiroshima University, Japan) Ikegami Tadashi (Tokyo Medical University Ibaraki Medical Center, Japan) Shimizu Masahito (Gifu University, Japan)	
Symposium 1-1 Keynote lecture	Functions of the glucose sensing pathway in health-span and lifespan Sheng-Cai Lin (Xiamen University / Chinese Academy of Sciences, China)	
Symposium 1-2 Keynote lecture	Bile acids and non-coding RNA in cholestatic liver disease Huiping Zhou (Virginia Commonwealth University, USA)	
Symposium 1-3 Keynote lecture	Chronic itch: from mechanism to drug discovery Xiaoguang Lei (Peking University, China)	
Symposium 1-4 Keynote lecture	Chenodeoxycholic acid, a primary bile acid, reduces stroke by reducing neuronal excitotoxicity Singaraja Roshni Rebecca (National University of Singapore, Singapore)	
Symposium 1-5 Keynote lecture	Social bonds retain oxytocin-mediated brain-liver axis to retard atherosclerosis Anzai Atsushi (Keio University, Japan)	
Symposium 1-6 Keynote lecture	The role of conjugated bile acids for muscle inflammatory responses and fiber types in chronic liver disease patients Eguchi Akiko (Mie University Hospital, Japan)	
Symposium 1-7	Metabolic and immune profiling of the hepatic encephalopathy Matsuda Michitaka (Dept. of Liver Disease / The Research Center for Hepatitis and Immunology / National Institute for Global Health and Medicine, Japan)	
Symposium 1-8	Pemafibrate improves liver function with alteration of bile acid composition and gut microbiota in patients with steatotic liverdisease Arase Yoshitaka (Tokai University, Japan)	
Symposium 1-9	Alterations in bile acid dynamics after bariatric and metabolic surgery: basic research using an obese rat model of duodenal-jejunal bypass Imoto Hirofumi (Tohoku University, Japan)	
Symposium 1-10	Esophageal carcinogenesis by reflux of bile acid into esophagus Hashimoto Naoki (Sanda city hospital ER, Japan)	

State-of-the-art Lecture 1		11:10-12:10
Chair	Takikawa Hajime (Teikyo University, Japan)	
Presenter	Leveraging bile acid signaling for the treatment of primary sclerosing cholangitis: lessons from norucholic acid (norUDCA/NCA) Michael Trauner (Medical University of Vienna, Austria)	
Luncheon Seminar 1 (AbbVie)		12:20-13:10
Chair	Terai Shuji (Niigata University, Japan)	
Presenter 1	Translating basic discoveries into therapies for HBV-related HCC Otsuka Motoyuki (Okayama University, Japan)	
Presenter 2	The last one mile for HCV elimination in Japan Ikegami Tadashi (Tokyo Medical University Ibaraki Medical Center, Japan)	
Workshop 1 : MASLD, Alcohol-associated liver disease		14:30-15:40
Chair	Ikejima Kenichi (Juntendo University, Japan) Yoshiji Hitoshi (Nara Medical University, Japan) Akuta Norio (Toranomon Hospital, Japan)	
Workshop 1-1	Causal analysis of steatotic liver disease based on linear mixed causal model using a cohort with comprehensive medical dataset Itoh Yoshito (Kyoto Prefectural University of Medicine, Japan)	
Workshop 1-2	Synergistic effect of fatty acid desaturase 2 (FADS2) and PNPLA3 risk alleles in fibrosis progression of MASLD Ikejima Shunsuke (Juntendo University, Japan)	
Workshop 1-3	Early dynamics of serum microRNA-122 predict therapeutic response to diet and exercise therapy in patients with steatotic liver disease Eriksson Yasuka (Toranomon Hospital Hepatology Department, Japan)	
Workshop 1-4	Prevalence and characteristics of MASLD in people with HIV: a single-center retrospective study in Japan Koga Michiko (The University of Tokyo, Japan)	
Workshop 1-5	Utility of shear wave elastography for predicting esophageal varices in MASH and ALD patients Nishimura Takashi (Hyogo Medical University / Hyogo Medical University Hospital, Japan)	
Workshop 1-6	Prognostic significance of skeletal muscle mass in patients with alcoholic cirrhosis Namisaki Tadashi (Nara Medical University, Japan)	
Workshop 1-7	Addiction therapy for Korean patients with alcoholic liver disease Jin-Wook Kim (Seoul National University Bundang Hospital, Korea)	

Panel Discussion 4 : In vitro models**15:45-17:35**

Chair	Inagaki Yutaka (Tokai University, Japan) Takami Taro (Yamaguchi University, Japan) Tomiya Tomoaki (Japan Organization of Occupational Health and Safety, Japan)
Panel Discussion 4-1 Keynote lecture	Liver tissue remodeling response to cholestatic injury Tanimizu Naoki (The University of Tokyo, Japan)
Panel Discussion 4-2 Keynote lecture	Analyses of pluripotent stem cell-derived liver culture system regulated by transcription factors Kamiya Akihide (Tokai University School of Medicine, Japan)
Panel Discussion 4-3 Keynote lecture	Three-dimensional biliary system reconstruction using hepatic progenitors and decellularized liver scaffold: toward clinical translation Hirukawa Kazuya (Kawasaki Municipal Hospital, Japan)
Panel Discussion 4-4 Keynote lecture	Impact on clinical decision making based on iPS cell-based modeling of multi-organ disorders, glycogen storage disease type 4 Asai Akihiro (Cincinnati Children's Hospital Medical Center, USA)
Panel Discussion 4-5	Long-term maintenance of hepatocyte characteristics in human iPSC-derived hepatic organoids (iHOs) via bile acid signaling Shimizu Taro (Institute of Science Tokyo, Japan)

DAY 1 : Thursday, 25 September, 2025**[Venue 2 - NISHIKI]****Panel Discussion 1 : Genetic liver diseases in pediatrics****8:00-10:10**

Chair	Inui Ayano (Saiseikai Yokohamashi Tobu Hospital, Japan) Kurosaki Masayuki (Musashino Red Cross Hospital, Japan) Kitamura Tsuneo (Juntendo University Urayasu Hospital, Japan)
Panel Discussion 1-1 Keynote lecture	Genetic liver diseases in pediatrics and young adults: a 2025 update Huey-Ling Chen (National Taiwan University Hospital, Taiwan)
Panel Discussion 1-2 Keynote lecture	Progressive familial intrahepatic cholestasis in India Seema Alam (Institute of Liver and Biliary Sciences, India)
Panel Discussion 1-3 Keynote lecture	Clinical, biochemical, and molecular characterization of bile acid synthesis disorders in a large case series from the Arabs Abdulrahman Al-Hussaini (King Fahad Medical City Clinic / Saudi Journal of Gastroenterology, Saudi Arabia)
Panel Discussion 1-4 Keynote lecture	Bile acid synthesis disorders in Japan: advances in diagnosis, herapeutic strategies, and the potential of neonatal screening Suzuki Mitsuyoshi (Juntendo University Faculty of Medicine, Japan)
Panel Discussion 1-5 Keynote lecture	CIRCLe: a nationwide patient registry advancing the diagnosis and treatment of childhood-onset liver disease Hayashi Hisamitsu (The University of Tokyo, Japan)
Panel Discussion 1-6 Keynote lecture	"Better is the enemy of good." How are the emerging molecular therapies going beyond liver transplant for genetic liver diseases? Asai Akihiro (Cincinnati Children's Hospital Medical Center, USA)

Panel Discussion 2 : Genetic liver diseases in adults**10:15-11:05**

Chair	Kanto Tatsuya (National Institute of Global Health and Medicine, Japan) Komuta Mina (International University of Health and Welfare, Japan)
Panel Discussion 2-1 Keynote lecture	Clinical utility of genomic analysis for diagnosis and management of adults with unexplained liver disease Silvia Vilarinho (Yale University, USA)
Panel Discussion 2-2 Keynote lecture	Toward precision genomic medicine: novel discoveries in rare and undiagnosed diseases Kosaki Kenjiro (Keio University, Japan)

Luncheon Seminar 2 (Chugai)**12:20-13:10**

Chair	Sakamoto Naoya (Hokkaido University, Japan)
Presenter	Evolving strategies and future directions of combination immunotherapy in unresectable hepatocellular carcinoma Tsuchiya Kaoru (Musashino Red Cross Hospital, Japan)

Chair	Komori Atsumasa (NHO Nagasaki Medical Center, Japan) Abe Masanori (Ehime University, Japan) Yoshio Sachiyo (National Institute of Global Health and Medicine, Japan)
Panel Discussion 3-1 Keynote lecture	Primary biliary cholangitis - overview Tanaka Atsushi (Teikyo University, Japan)
Panel Discussion 3-2 Keynote lecture	Lymphatic dysfunction in PBC: toward a new paradigm in liver disease Iwakiri Yasuko (Yale University, USA)
Panel Discussion 3-3 Keynote lecture	Pathological significance of IDO-1 expression in intrahepatic bile ducts of primary biliary cholangitis Harada Kenichi (Kanazawa University, Japan)
Panel Discussion 3-4	Hepatic deposition of orcein-positive granules predicts responsiveness to ursodeoxycholic acid in primary biliary cholangitis Morinaga Maki (Juntendo University, Japan)

Workshop 2 : HCC**16:00-17:30**

Chair	Sakamoto Michiie (International University of Health and Welfare, Japan) Tateishi Ryosuke (The University of Tokyo Hospital, Japan) Nouso Kazuhiro (Okayama City Hospital, Japan)
Workshop 2-1	Peripheral immune cell markers associated with Atezo/Bev non-response in unresectable HCC Namba Hiromasa (National Institute of Global Health and Medicine / Hokkaido University Hospital, Japan)
Workshop 2-2	Circulating miR-485-3p as a biomarker for VEGF-mediated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma Oura Kyoko (Kagawa University, Japan)
Workshop 2-3	Depth of tumor marker response as a predictor of treatment efficacy in patients with hepatocellular carcinoma undergoing durvalumab plus tremelimumab Saeki Issei (Yamaguchi University / Hepatology InVestigator Experts in Japan Study Group, Japan)
Workshop 2-4	Efficacy and safety of atezolizumab plus bevacizumab after durvalumab plus tremelimumab for hepatocellular carcinoma Uchikawa Shinsuke (Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Japan)
Workshop 2-5	Advancing precision surgery: VR holography-guided anatomical liver resections in eight consecutive cases Kawashita Yujo (Fukuoka Seisyukai Hospital, Japan)

Workshop 2-6

Cancelled

Workshop 2-7	ER stress-induced hepatic stellate cells promote hepatocellular carcinoma progression via the PERK/p38 δ MAPK/IL-1 β axis Morita Makoto (Ehime University, Japan)
Workshop 2-8	The DNA double strand break repair deficiency of hepatocellular carcinoma in Fontan associated liver disease Yamazoe Taiji (Japan Institute for Health Security, Japan)

Evening Seminar (Kowa)**17:40-18:20**

Chair	Tanaka Naoki (Shinshu University, Japan)
Presenter	Management of metabolic, cardiac and liver diseases in MASLD Tamaki Nobuharu (Musashino Red Cross Hospital, Japan)

DAY 2 : Friday, 26 September, 2025**[Venue 1 - OHGI]****Morning Seminar 1 (AbbVie)****7:30-8:20**

Chair	Ueno Yoshiyuki (Yamagata University, Japan)
Presenter 1	Treatment strategies for chronic liver disease caused by HIV/HCV coinfection Kimura Kiminori (Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan)
Presenter 2	Essential factors for eliminating hepatitis C virus Hiasa Yoichi (Ehime University, Japan)

Symposium 2 : Experimental animal models**8:30-11:05**

Chair	Honda Akira (Tokyo Medical University Ibaraki Medical Center, Japan) Makishima Makoto (Nihon University, Japan) Terai Shuji (Niigata University, Japan)
Symposium 2-1 Keynote lecture	Therapeutic potential of targeting the renal apical sodium-dependent bile acid transporter for cholestatic liver disease and cholemic nephropathy Paul A. Dawson (Emory University, USA)
Symposium 2-2 Keynote lecture	Deletion of hepatic FXR leads to more severe MASH development in female mice Grace L. Guo (Rutgers University, USA)
Symposium 2-3 Keynote lecture	Oxysterol is a possible mechanistic target for MASLD treatment: lessons from dietary study in CYP7B1 knockout and transgenic mouse models Kakiyama Genta (Virginia Commonwealth University / Central Virginia VA Health Care System, USA)
Symposium 2-4 Keynote lecture	A gut-liver axis in progressive familial intrahepatic cholestasis type 1: ATP8B1 loss induces choline-deficient steatohepatitis Hayashi Hisamitsu (The University of Tokyo, Japan)
Symposium 2-5 Keynote lecture	Characteristics of a mouse model that mimics human bile acid composition Honda Akira (Tokyo Medical University Ibaraki Medical Center, Japan)
Symposium 2-6	Development of PFIC mouse models with human-like bile acid composition via liver-specific CRISPR/ Cas9-mediated gene deletion Tsuruya Kota (Tokai University, Japan)
Symposium 2-7	Heterozygous knockout of bile salt export pump induces alterations in the gut-liver axis including gut microbiota in mice fed a high-fat diet Okushin Kazuya (The University of Tokyo, Japan)
Symposium 2-8	Dominant-inhibition of RXR α prevents high-fat diet-induced obesity and liver steatosis in mice by regulating food intake and energy expenditure Sakai Hiroyasu (Gifu University, Japan)

State-of-the-art Lecture 2	11:10-12:10
-----------------------------------	--------------------

Chair	Takehara Tetsuo (Kansai Rosai Hospital, Japan)
Presenter	Novel vagal hepatic nerve stimulation (VHNS) for enhancing intestinal regulatory T cells through tuning the central nervous system Kanai Takanori (Keio University, Japan)

Luncheon Seminar 3 (Gilead Sciences)	12:15-13:05
---	--------------------

Chair	Nakamoto Yasunari (University of Fukui, Japan)
Presenter	Hepatitis B treatment: latest trends and strategies for addressing challenges Suda Goki (Hokkaido University, Japan)

State-of-the-art Lecture 3	14:20-15:20
-----------------------------------	--------------------

Chair	Kawada Norifumi (Osaka Metropolitan University, Japan)
Presenter	Precision microbiota editing for alcohol-associated liver disease Bernd Schnabl (University of California San Diego, USA)

Symposium 3 : Microbiota in liver diseases and organ crosstalk	15:25-16:20
---	--------------------

Chair	Ito Yoshito (Kyoto Saiseikai Hospital, Japan) Nakajima Atsushi (International University of Health and Welfare, Japan) Yoneda Masashi (Shinbashi Clinic / Aichi Medical University, Japan)
Symposium 3-1 Keynote lecture	Microbiota in liver diseases and organ crosstalk : microbiota in liver diseases Ki Tae Suk (Hallym University Medical Center, Korea)
Symposium 3-2	Quantification of streptococcus spp using the digital polymerase chain reaction as a liver fibrosis marker in patients with chronic liver disease Uojima Haruki (Kitasato University, Japan)
Symposium 3-3	The study of gut mucosa-associated microbiota dysbiosis and muscle atrophy in patients after sustained virologic response to hepatitis C virus Saito Arisa (University of Fukui, Japan)
Symposium 3-4	Activation of hepatocyte p53 upregulates leukemia inhibitory factor (LIF) and triggers acute liver failure with multiple organ injury Sung Jihyun (Osaka University, Japan)

Closing Remarks	16:25-16:30
------------------------	--------------------

Kagawa Tatehiro

DAY 2 : Friday, 26 September, 2025**[Venue 2 - NISHIKI]****Morning Seminar 2 (Roche Diagnostics)****7:30-8:20**

Chair	Izumi Namiki (Japanese Red Cross Musashino Hospital, Japan)
Presenter	Optimizing clinical pathways through simultaneous HCV antibody-antigen (Duo) testing: advancing early diagnosis and timely access to treatment Tanaka Yasuhito (Kumamoto University, Japan)

Panel Discussion 5 : PSC**8:30-9:40**

Chair	Taniai Makiko (Tokyo Women's Medical University, Japan) Nagano Hiroaki (Yamaguchi University, Japan) Kawaguchi Takumi (Kurume University, Japan)
Panel Discussion 5-1 Keynote lecture	Role of gut microbiota in the pathogenesis of primary sclerosing cholangitis Nakamoto Nobuhiro (Keio University, Japan)
Panel Discussion 5-2 Keynote lecture	Anti-integrin $\alpha\beta 6$ autoantibodies in patients with primary sclerosing cholangitis Shiokawa Masahiro (Kyoto University, Japan)
Panel Discussion 5-3	Onset of PSC by lithocholic acid administration in a Cyp2c70-/-/Cyp2a12-/- mouse with human-type bile acid composition through the gut-bile duct axis Miyazaki Teruo (Tokyo Medical University Ibaraki Medical Center, Japan)
Panel Discussion 5-4	Effects of haskap fruit extract on model mice of primary sclerosing cholangitis Dungubat Erdenetsogt (Tokyo Medical University, Japan)

Sponsored Seminar (AbbVie)**9:50-10:40**

Chair	Tanaka Yasuhito (Kumamoto University, Japan)
Presenter 1	Recent topics on liver cirrhosis Tsuchiya Atsunori (University of Yamanashi, Japan)
Presenter 2	Treatment strategies for chronic hepatitis C based on real-world data Atsukawa Masanori (Nippon Medical School, Japan)

Luncheon Seminar 4 (Eisai)**12:15-13:05**

Chair	Mochida Satoshi (Saitama Medical University, Japan)
Presenter 1	Significance of surgical intervention as a part of multidisciplinary approach for advanced hepatocellular carcinoma Shindoh Junichi (Toranomon Hospital, Japan)
Presenter 2	The current and future role of lenvatinib in multidisciplinary treatment strategy for hepatocellular carcinoma Kawamura Yusuke (Saitama Medical University, Japan)

Chair	Yotsuyanagi Hiroshi (The Institute of Medical Science, The University of Tokyo, Japan) Watanabe Tsunamasa (St. Marianna University, Japan) Saito Hidetsugu (Kitasato University Kitasato Institute Hospital, Japan)
Workshop 3-1	Screening of FDA approved drug library for compounds that reduce HBs antigen expression Murai Kazuhiro (The University of Osaka, Japan)
Workshop 3-2	IFN vs. DAA impact on bone metabolism in CHC: transcriptomic & clinical study Lin Jung-Chun (National Defense Medical Center, Taiwan)
Workshop 3-3	HCV clearance improves the branched-chain amino acid to tyrosine ratio (BTR) of patients with mild-to-advanced fibrosis Mino Masaaki (Japan Institute for Health Security, Japan)
Workshop 3-4	Plasma XOR of various liver diseases may reflect serum ALT level rather than liver disease progression Sato Ken (Gunma University / Heisei Hidaka Clinic / Takasaki University of Health and Welfare, Japan)
Workshop 3-5	Novel therapeutic strategy for portopulmonary hypertension targeting portosystemic shunts Ishikawa Tsuyoshi (Yamaguchi University, Japan)
Workshop 3-6	Rifaximin suppressed overt hepatic encephalopathy during lenvatinib therapy in patients with hepatocellular carcinoma and splenorenal shunt Kawaguchi Takumi (Kurume University School of Medicine, Japan)

Poster Session Program

DAY 1 : Thursday, 25 September, 2025

Poster Session Day 1 13:20-14:20

HCC (1)

Chair	Hasegawa Kiyoshi (The University of Tokyo, Japan)
Poster 1-1-1	A new diagnostic approach: glycosylated ferritin-based index for hepatocellular carcinoma Ishiguro Akiyo (Yamaguchi University, Japan)
Poster 1-1-2	Noninvasive quantitative assessment of pH in liver cancer using phosphorus-31 magnetic resonance spectroscopy Ozaki Kumi (Hamamatsu University, Japan)
Poster 1-1-3	Multi-omics analysis of the mechanism of overcoming resistance to multi-kinase inhibitors in hepatocellular carcinoma cell lines Fujita Koji (Kagawa University, Japan)
Poster 1-1-4	Impact of mean liver dose on ALBI score deterioration after SBRT for HCC: a joint modeling approach Kishi Noriko (Kyoto University, Japan)

Alcohol

Chair	Shiraishi Koichi (Tokai University, Japan)
Poster 1-2-1	Discrepancy between alcohol metabolism gene polymorphisms and self-recognition in patients with alcoholic cirrhosis Tadokoro Tomoko (Kagawa University School of Medicine, Japan)
Poster 1-2-2	Elafibranor ameliorates liver fibrosis development and repairs gut barrier function in a mouse alcohol-associated liverdisease model Kaji Kosuke (Nara Medical University, Japan)
Poster 1-2-3	Reduction of alcohol intake improves gut dysbiosis, and carbohydrate-deficient transferrin is a useful marker for assessing alcohol consumption Kumagai Masaru (Niigata University, Japan)
Poster 1-2-4	Analysis of portal blood microbiota in alcohol-related liver cirrhosis - impact of alcohol consumption on liver pathophysiology via leaky gut Shigefuku Ryuta (Mie University, Japan)

Liver cirrhosis (1)

Chair	Yamasaki Takahiro (Yamaguchi University, Japan)
Poster 1-3-1	Stimulatory effect of insulin-like growth factor I on collagen degradation system reduces collagen production by hepatic stellate cells Nishikawa Takako (The University of Tokyo Hospital, Japan)
Poster 1-3-2	Involvement of cannabinoid 1 receptors in liver fibrosis Ishizuka Kei (Juntendo University, Japan / University of California San Diego, USA)
Poster 1-3-3	Lipopolysaccharide binding protein as a potential predictive biomarker for acute kidney injury onset in cirrhosis Masuda Hiroyuki (Nara Medical University, Japan)
Poster 1-3-4	ADAMTS13 deficiency exaggerates acute kidney injury in mice with liver fibrosis. Nishimura Norihisa (Nara Medical University, Japan)

Genetic disease

Chair	Nakagawa Mina (Institute of Science Tokyo, Japan)
Poster 1-4-1	A case of RELA mutation involving chronic liver injury and systemic inflammatory response Imagawa Kazuo (University of Tsukuba, Japan)
Poster 1-4-2	Utility of combined genetic testing and bile acid analysis in the early diagnosis of zellweger syndrome: a case report Saito Hiroki (Juntendo University Faculty of Medicine, Japan)
Poster 1-4-3	Pathogenic variants in the LSR gene present with a PFIC-like clinical phenotype Takaki Yugo (Japanese Red Cross Kumamoto Hospital, Japan)
Poster 1-4-4	A case of GATA6 deficiency with progressive cholestasis Ito Shogo (Nagoya City University, Japan)

HCC (2), Others

Chair	Tsuchiya Kaoru (Musashino Red Cross Hospital, Japan)
Poster 1-5-1	Reduced health-related quality of life predicts poor outcomes in advanced hepatocellular carcinoma patients treated with atezolizumab and bevacizumab Shomura Masako (Tokai University, Japan)
Poster 1-5-2	Hepatocellular carcinoma rupture after introducing atezolizumab plus bevacizumab combination therapy: a case report Tada Kazuhiro (Oita Red Cross Hospital, Japan)
Poster 1-5-3	Drug-induced steatohepatitis and fibrosis in a female patient with persistent atrial fibrillation treated with amiodarone: a case report Kakita Naruyasu (Kaizuka City Hospital, Japan)
Poster 1-5-4	Metabolic dysfunction-associated steatotic liver disease as a risk factor for gallstone development: a multicenter cohort study Fukunaga Shuhei (Kurume University School of Medicine, Japan)

MASLD

Chair	Kawanaka Miwa (Okayama University, Japan)
Poster 1-6-1	Deletion of StarD5 promotes hepatic steatosis and progression of fibrosis Daniel Rodriguez-Agudo (Virginia Commonwealth University / Central Virginia VA Health Care System, USA)
Poster 1-6-2	Stigma of patients with metabolic dysfunction associated steatotic liver disease: a single-center study in Japan Shibayama Kaoru (Saga University, Japan)
Poster 1-6-3	Elobixibat, an ileal bile acid transporter inhibitor, ameliorates nonalcoholic steatohepatitis in mice Yamauchi Ryo (Fukuoka University, Japan)
Poster 1-6-4	A study protocol to evaluate the effectiveness of cognitive behavioral therapy in optimizing lifestyle behaviors in patients with MASLD Sato Emi (Tokyo Medical University, Japan)

Bile acids

Chair	Shimoda Shinji (Kansai Medical University, Japan)
Poster 1-7-1	Cancelled
Poster 1-7-2	Taurine-conjugated primary bile acids contribute to the pathogenesis of portal hypertension via endothelial cell injury Shigefuku Ryuta (Mie University, Japan)
Poster 1-7-3	Impact of gadexetic acid-enhanced MRI on prediction of pharmacokinetics and adverse events of drugs as substrates of OATP1B1/1B3 Okubo Hironao (Juntendo University Nerima Hospital, Japan)
Poster 1-7-4	Dual pathogenic mechanisms in lysinuric protein intolerance: interplay between hyperammonemia and cellular metabolic dysregulation in astrocyte injury Kakisaka Keisuke (Iwate Medical University, Japan)
Poster 1-7-5	Serum conjugated bile acid levels reflect disease severity and predict survival in chronic liver disease in both humans and rats Eguchi Akiko (Mie University Hospital, Japan)

DAY 2 : Friday, 26 September, 2025**Poster Session Day 2 13:10-14:10****HCC (3)**

Chair	Morimoto Manabu (Yokohama City University Medical Center, Japan)
Poster 2-1-1	Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable HCC Chuma Makoto (Yokohama City University Medical Center / Yokohama Hodogaya Central Hospital, Japan)
Poster 2-1-2	Impact of skeletal muscle volume loss during atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma: a multicenter study Fujita Masashi (Fukushima Medical University, Japan)
Poster 2-1-3	Potential biomarkers for severe adverse events in atezolizumab/ bevacizumab therapy: von Willebrand factor and ADAMTS13 Takaya Hiroaki (Nara Medical University / Nara Prefecture Seiwa Medical Center, Japan)
Poster 2-1-4	The effect of corticosteroid use on prognosis during atezolizumab + bevacizumab combination therapy Hirose Shunji (Tokai University Hachioji Hospital, Japan)

HCC (4)

Chair	Okubo Hironao (Juntendo University Nerima Hospital, Japan)
Poster 2-2-1	Regional differences in liver cancer morbidity and radical treatments in Japan: analysis using the national database of health insurance claims Nakano Masahito (Kurume University, Japan)
Poster 2-2-2	Serum CRP as a prognostic biomarker in advanced HCC treated with durvalumab and tremelimumab: a multicenter study Yata Yutaka (Hanwa Memorial Hospital / RELPEC Study group / HCC 48 group, Japan)
Poster 2-2-3	Eosinophilic hepatitis presenting as multiple hepatic mass lesions after curative resection of hepatocellular carcinoma Kakita Naruyasu (Kaizuka City Hospital, Japan)
Poster 2-2-4	Early Immune-related hepatitis after Initiation of durvalumab and tremelimumab in a patient with hepatocellular carcinoma Suzuki Fumiya (Yamagata University Faculty of Medicine, Japan)

Liver cirrhosis (2)

Chair Nagoshi Sumiko
(Saitama Medical Center, Japan)

Poster 2-3-1

Cancelled

Poster 2-3-2 Tofogliflozin delays portal hypertension and hepatic fibrosis by inhibiting sinusoidal capillarization in cirrhotic rats
Asada Shohei
(Nara Medical University, Japan)

Poster 2-3-3 Splenectomy for patients with liver cirrhosis of Child-Pugh classification C
Okada Takuma
(Toranomon Hospital, Japan)

Poster 2-3-4 Efficacy of strain elastography in the evaluation of liver fibrosis in postoperative fontan patients
Tanaka Masatake
(Kyushu University Hospital, Japan)

HCV

Chair Atsukawa Masanori
(Nippon Medical School, Japan)

Poster 2-4-1 Baseline bone mineral density predicts long-term outcomes after interferon therapy for chronic hepatitis C: a retrospective cohort study
Pei-Tzu Chen
(National Defense Medical Center, Taiwan)

Poster 2-4-2 A case of chronic hepatitis C in which HCV elimination may have been achieved by a combination of factors including remdesivir administration
Sato Ken
(Gunma University / Heisei Hidaka Clinic / Takasaki University of Health and Welfare, Japan)

Poster 2-4-3 Effective HCV detection using the Elecsys HCV Duo assay
Sato Shunsuke
(Juntendo University Shizuoka Hospital, Japan)

Poster 2-4-4 The usefulness of a simultaneous immunoassay for HCV antigen-antibody using the Elecsys HCV Duo assay
Amano Keisuke
(Kurume University Hospital, Japan)

HBV, HDV

Chair	Takaguchi Koichi (Kagawa Prefectural Central Hospital, Japan)
Poster 2-5-1	Therapeutic efficacy of monoclonal antibodies in the treatment of hepatitis B virus in a mouse model Maidina Abuduwaili (Hiroshima Life Science Institute, Japan)
Poster 2-5-2	Suppression of HSPG2 expression inhibits HBV entry and replication via cMET signaling pathway Murai Kazuhiro (The University of Osaka, Japan)
Poster 2-5-3	Hepatitis D virus (HDV) may possess oncogenic potential through the induction of genomic instability Sato Shinya (Nara Medical University, Japan)
Poster 2-5-4	A case of chronic hepatitis B vietnamese woman living in Japan presumed to have been horizontally infected with HBV-B4 strain from father to daughter Sato Ken (Gunma University / Takasaki University of Health and Welfare, Japan)

Viral infection

Chair	Ebinuma Hirotochi (International University of Health and Welfare, Japan)
Poster 2-6-1	COVID-19 vaccine-induced liver injury update Sato Ken (Gunma University, Japan)
Poster 2-6-2	Exploratory and predictive analytics of COVID-19's impact on liver cancer outcomes Monirujjaman Biswas (Jawaharlal Nehru University, India)
Poster 2-6-3	Efficient deep learning framework for nucleus segmentation from the histopathological images in liver cancer Monirujjaman Biswas (Jawaharlal Nehru University, India)
Poster 2-6-4	Hepatitis E virus-associated Guillain-Barr syndrome in HBV carrier: a case report Hirasawa Yuka (Juntendo University Urayasu Hospital, Japan)

Gut microbiota

Chair	Eguchi Akiko (Mie University / Mie University Hospital, Japan)
Poster 2-7-1	Mechanism of gut microenvironment restoration induced by HCV eradication Inoue Takako (Nagoya City University Hospital, Japan)
Poster 2-7-2	Association of duodenal periodontal bacteria with advanced liver fibrosis in metabolic dysfunction-associated steatotic liver disease Niida Kazuki (Ehime University, Japan)
Poster 2-7-3	Evaluation of the risk of Clostridium difficile infection using a serum bile acid profile Monma Tadakuni (Tokyo Medical University Ibaraki Medical Center, Japan)

Experimental models

Chair	Tanaka Naoki (Shinshu University, Japan)
Poster 2-8-1	A new mouse model of metabolic dysfunction-associated steatohepatitis with HCC in human-like conditions Ueda Hajime (Tokyo Medical University Ibaraki Medical Center, Japan)
Poster 2-8-2	Generation of liver-specific FXR-deficient mice with a human-like bile acid profile and development of novel therapeutic approaches Mishima Yusuke (Tokai University, Japan)
Poster 2-8-3	Changes in bile acid metabolism and intestinal flora after total gastrectomy Hashimoto Naoki (Sanda City Hospital ER, Japan)